SynthesisJournal of cutaneous pathology2026
Desmoplastic Cutaneous Squamous Cell Carcinoma Is an Aggressive and Potentially Fatal Skin Cancer: A Systematic Review.
Synthesis in Journal of cutaneous pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The incidence and mortality of cutaneous squamous cell carcinoma (cSCC) are increasing. Desmoplastic cSCC (dcSCC) is an uncommon yet highly aggressive variant which has received relatively little attention in the literature. No systematic reviews of dcSCC are currently available. This paper aims to summarize the current understanding of the behavior of dcSCC by conducting a systematic review of published series with particular focus on outcomes. A comprehensive search was conducted for original series in English. Six studies reporting a total of 286 dcSCC were included in the final analysis. Most series were single site and retrospective. Pooled estimates demonstrated local recurrence rate 30% (95% CI: 24%-36%, p = 0.765), nodal metastasis 17% (95% CI: 12%-22%, p = 0.158), distant metastasis 5% (95% CI: 2%-9%, p = 0.574) and disease-specific death 12% (95% CI: 3%-36%, p = 0.047), outcomes which are considerably worse than non-dcSCC. The findings confirm the aggressive nature of dcSCC and suggest early aggressive treatment is warranted. However, given the limitations of existing studies, there is a need for large, prospective, multicentre studies to better define prognostic factors and optimize management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.